Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors

NCT03407716 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-01-05

No results posted yet for this study

Summary

This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors. Ginseng may decrease fatigue in people who were treated for cancer.

Conditions

  • Cancer Survivor
  • Stage I Breast Cancer AJCC v7
  • Stage I Colon Cancer AJCC v6 and v7
  • Stage IA Breast Cancer AJCC v7
  • Stage IB Breast Cancer AJCC v7
  • Stage II Breast Cancer AJCC v6 and v7
  • Stage II Colon Cancer AJCC v7
  • Stage IIA Breast Cancer AJCC v6 and v7
  • Stage IIA Colon Cancer AJCC v7
  • Stage IIB Breast Cancer AJCC v6 and v7
  • Stage IIB Colon Cancer AJCC v7
  • Stage IIC Colon Cancer AJCC v7
  • Stage III Breast Cancer AJCC v7
  • Stage III Colon Cancer AJCC v7
  • Stage IIIA Breast Cancer AJCC v7
  • Stage IIIA Colon Cancer AJCC v7
  • Stage IIIB Breast Cancer AJCC v7
  • Stage IIIB Colon Cancer AJCC v7
  • Stage IIIC Breast Cancer AJCC v7
  • Stage IIIC Colon Cancer AJCC v7

Interventions

DRUG

American Ginseng

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo

Given PO

OTHER

Questionnaire Administration

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Noel Arring · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2020-05-13
Completion
2021-02-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03407716 on ClinicalTrials.gov